take two key pushback
resum ow rate may two key
investor pushback appear expos
unemploy humira pend cliff much
overhang respons plu highlight
remain bullish view humira eros fear overli discount
prospect underappreci pt repres
trough ep expect multipl expand come year
importantli see fewer patent cliff post-humira peer think
market under-appreci growth trajectori mid-lat vs
group early-stag pipelin surpris upsid think market
could start price bull case valuat
face unemploy risk us sale stock
valuat yield still attract trade ep
offer dividend yield estim us commerci exposur
highest global sale would note estim lilli
commerci exposur global sale share trade
ep group estim highest-to-lowest us commerci
exposur percentag global sale follow
exhibit also expos us cash pay
estimate global sale includ aesthet
regard humira eros risk see instead focu beyond
estim humira consensu off-set higher ex-
humira sale ms vs con exhibit emphas
gentlest cliff estim revenu
risk gener biosimilar competit smallest
percentag five compani project sale expos biosimilar
gener eros follow lowest highest
biopharma exhibit exhibit
wildcard catalyst immin plan issu press releas abbv-
phase result soon antibody-drug conjug
consist anti-tnf antibodi steroid technolog could
repres new deliveri platform assum low odd success
yet demonstr human efficaci proof-of-concept result
major pharmaceut unit state america
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
phase data surprisingli compel think share could step higher
fail share may trade slightli platform concept
abl deliv drug case steroid specif target
case immun cell via antibodi case tnf
accompani system side effect technolog success could
repres platform broad applic note state
caus system side effect preclin phase human
studi await phase poc efficaci result rheumatoid arthriti
long-term safeti data refer wildcard catalyst section
exhibit allergan payer mix global revenu
exhibit us sale payer exposur percentag global revenu compani rank
base exposur commerci busi pro forma agn sale
us sale other includ medicaid va dod medicar part other
visibl alpha research estim
exhibit revenu exposur gener biosimilar competit
sale risk gx/biosim competit
exhibit patent cliff order revenu exposur grey row small molecul white
row biolog complex formul gener face less steep declin
sale sale patent expir
ex-u biosim enter late
us estimate assum gx sinc intestitin pump
 assum gx sinc implant
exhibit patent cliff order revenu exposur grey row small molecul white
row biolog complex formul gener face less steep declin
sale total sale patent expir
 assum teva gx
exhibit patent cliff order revenu exposur grey row small molecul white
row biolog complex formul gener face less steep declin
sale total salespat expir
exhibit patent cliff order revenu exposur grey row small molecul white
row biolog complex formul gener face less steep declin
sale total sale patent expir
ex-u eu jun spc jul jpn feb
exhibit patent cliff order revenu exposur grey row small molecul white
row biolog complex formul gener face less steep declin
sale sale patent expir
anti-tnf antibodi steroid combo could
transform efficaci long-term safeti need demonstr
expect ph proof concept data may-jun
exhibit deliv steroid immun cell target
manner theoret would demonstr durabl inhibit
inflamm system side effect
head michael severino highlight
potenti transform call
antibody-drug conjug consist anti-tnf antibodi
steroid idea abl deliv drug
case steroid specif target case immun
cell via antibodi case tnf
accompani system side effect technolog success
could platform would broad applic mani
phase poc data iv expect soon
call proof-of-concept phase trial ra expect read
soon trial evalu
anoth tnf-steroid dose iv humira dose
subcutan primari endpoint week estim
primari complet june
phase studi sq show impact serum
cortisol level dose subcutan mg
mg healthi volunt show impact serum
cortisol level similar placebo day post-dos contrast
prednison mg depress serum cortisol level day post-dos exhibit
phase data encourag await ph proof efficaci long-term
safeti understand seen flatlin diseas anim
model hope phase poc show efficaci least compar humira
better safeti addit phase data use subcutan formul
phase ra trial dose iv await clariti rout
exhibit dose subcutan phase show chang serum cortisol
valuat methodolog risk
pt base base case ep price-to-earnings multipl peer
mean due product humira eros
risk upsid
sale result expect allergan cost synergi upsid posit pipelin
surpris value-enhanc activ
risk downsid
result expect pipelin disappoint drug reimburs challeng
competit threat disappoint problemat legal develop
